Subscription recommendations:
Established in 2010, the company is a biotechnology company dedicated to developing bispecific antibody (BsAb) -based therapies for the treatment of cancer-related complications, cancer, and senile ophthalmologic diseases. The company has designed and developed seven clinical-stage drug candidate pipelines, including the company's core product, M701, which is a recombinant BSAb that targets EpcAM-expressing cancer cells and CD3-expressing T cells. M701 uses epCAM as the target for tumor cells and CD3 as the target for T cells, combining tumor cells and T cells.
M701 binds to epCAM, so it can block downstream signals of EpCAM and inhibit tumor growth.
By binding to the T-cell surface antigen CD3, M701 promotes T-cell activation and proliferation, and releases cytokines to kill tumor cells. M701 also showed cytotoxicity to tumor cells through antibody-dependent cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). The company is currently conducting phase II clinical trials to treat patients with malignant ascites (MA) and phase Ib/II clinical trials to treat malignant pleural effusion (MPE). The M701 currently being developed by the company is mainly used for palliative treatment of MA and MPE (serious complications of cancer where fluid accumulates in the abdominal or thoracic cavity of cancer patients). The company plans to conduct a critical/phase III trial of M701 treatment MA in China in the first quarter of 2024 and submit the BLA for filing in the first quarter of 2025. The company is developing another product, Y101D (a recombinant anti-PD-L1 and anti-TGF-beta humanized BSAB) to treat solid tumors. Y101D was developed to simultaneously inhibit the PD-1/PD-L1 axis and the TGF-beta signaling pathway, thereby having the potential to release synergistic anti-tumor activity and mitigate drug resistance. The company began a phase Ib/II clinical trial of Y101D combination therapy to treat advanced/metastatic pancreatic cancer in February 2023.
After listing, the company's stock market value is estimated to be HK$3088-3,860 million. The company's anti-drug drug is highly innovative and has a strong competitive advantage, so it is recommended to purchase carefully.